Actinium Pharmaceuticals to Present at the 3rd Annual Targeted Radiopharmaceuticals Summit US

Actinium Pharmaceuticals (NYSE AMERICAN: ATNM) will present at the 3rd Annual Targeted Radiopharmaceuticals Summit US in San Diego from July 30 - August 1, 2024.

Rhea-AI Summary

Actinium Pharmaceuticals (NYSE AMERICAN: ATNM) will present at the 3rd Annual Targeted Radiopharmaceuticals Summit US in San Diego from July 30 - August 1, 2024. The presentation, titled 'Overcoming Adverse Cytogenetics, TP53, Other Mutations & Treatment Resistant Disease in Relapsed/Refractory AML Using Antibody Radiation Conjugates,' will take place on July 31, 2024.

The presentation will highlight:

• Iomab-B, a CD45 I-131 ARC, enabling bone marrow transplant in otherwise ineligible patients
• Actimab-A, a CD33 Ac-225 ARC, demonstrating strong anti-leukemic activity
• Responses in heavily pretreated patients, including those with prior venetoclax treatment or TP53-mutated disease
• Preclinical data showing benefits of combining Actimab-A with targeted therapies like FLT3 inhibitors

Both Iomab-B and Actimab-A are the only clinical stage antibody radiation conjugates in development for acute myeloid leukemia patients.

Argus Session date unavailable

+2.07% session move Open Argus

Details

News Market Reaction – ATNM

The recorded move for ATNM in the trading session of this news was +2.07%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

• Presentation to highlight positive outcomes of Iomab-B led bone marrow transplant in difficult to treat TP53 patients and the mutation-agnostic mechanism of Actimab-A for patients with relapsed or refractory acute myeloid leukemia
• Iomab-B and Actimab-A represent the only clinical stage antibody radiation conjugates in development for patients with acute myeloid leukemia

NEW YORK, July 25, 2024 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of Antibody Radiation Conjugates (ARCs) and other targeted radiotherapies, today announced that the Company will participate in the 3^rd Annual Targeted Radiopharmaceuticals Summit US, being held in San Diego, CA, from July 30 – August 1, 2024. Actinium's presentation titled, "Overcoming Adverse Cytogenetics, TP53, Other Mutations & Treatment Resistant Disease in Relapsed/Refractory AML Using Antibody Radiation Conjugates," will take place on Wednesday, July 31, 2024^th. The presentation will highlight the following:

• Exploring Iomab-B, a CD45 I-131 ARC, to enable bone marrow transplant (BMT) in otherwise ineligible patients, while Actimab-A, a CD33 Ac-225 ARC, demonstrates strong anti-leukemic activity
  
  
• Outlining responses in heavily pretreated patients for both Iomab-B and Actimab-A, including prior venetoclax treatment or TP53-mutated disease, to demonstrate how targeted radiotherapies offer broad therapeutic potential as backbone regimens
  
  
• Revealing preclinical data to further show the benefits of combining Actimab-A with targeted therapies, such as FLT3 inhibitors, to enhance anti-tumor response

For more information about the Targeted Radiopharmaceutical Summit and the conference agenda, please visit https://targeted-radiopharma-us.com/. 

About Actinium Pharmaceuticals, Inc.

Actinium develops targeted radiotherapies to meaningfully improve survival for people who have failed existing oncology therapies. Advanced pipeline candidates Iomab-B (pre-BLA & MAA (EU)), an induction and conditioning agent prior to bone marrow transplant, and Actimab-A (Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute), a therapeutic agent, have demonstrated potential to extend survival outcomes for people with relapsed and refractory acute myeloid leukemia. Actinium plans to advance Iomab-B for other blood cancers and next generation conditioning candidate Iomab-ACT to improve cell and gene therapy outcomes. Actinium holds more than 230 patents and patent applications including several patents related to the manufacture of the isotope Ac-225 in a cyclotron.

For more information, please visit: https://www.actiniumpharma.com/ 

Contact: 
investorrelations@actiniumpharma.com 

View original content to download multimedia:https://www.prnewswire.com/news-releases/actinium-pharmaceuticals-to-present-at-the-3rd-annual-targeted-radiopharmaceuticals-summit-us-302206068.html

SOURCE Actinium Pharmaceuticals, Inc.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What is Actinium Pharmaceuticals presenting at the 3rd Annual Targeted Radiopharmaceuticals Summit US?

Actinium Pharmaceuticals (ATNM) is presenting 'Overcoming Adverse Cytogenetics, TP53, Other Mutations & Treatment Resistant Disease in Relapsed/Refractory AML Using Antibody Radiation Conjugates' on July 31, 2024, highlighting their Iomab-B and Actimab-A therapies.

What are Iomab-B and Actimab-A, and how do they differ?

Iomab-B is a CD45 I-131 Antibody Radiation Conjugate (ARC) that enables bone marrow transplant in otherwise ineligible patients. Actimab-A is a CD33 Ac-225 ARC that demonstrates strong anti-leukemic activity. Both are in clinical stage development for acute myeloid leukemia patients.

How effective are Actinium's ARCs in treating patients with TP53 mutations?

Actinium's presentation will outline responses in heavily pretreated patients, including those with TP53-mutated disease, demonstrating how their targeted radiotherapies offer broad therapeutic potential as backbone regimens for difficult-to-treat patients.

What preclinical data will Actinium Pharmaceuticals (ATNM) reveal at the summit?

Actinium will reveal preclinical data showing the benefits of combining Actimab-A with targeted therapies, such as FLT3 inhibitors, to enhance anti-tumor response in acute myeloid leukemia patients.